Exploratory study on relationship between antidepressant effects and changes in the intestinal environment due to Hangekobokuto administration.

Exploratory study on relationship between antidepressant effects and changes in the intestinal environment due to Hangekobokuto administration. - Exploratory study on changes in the intestinal environment due to Hangekobokuto administration.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045707

Enrollment

Registered

2021-10-08

Start date

2021-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive symptoms

Interventions

Taking the Kampo medicine (Hangekobokuto) for 2 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Subjects aged 20-74. ?Subjects whose Beck Depression Inventory - Second Edition score are between 14 to 28 points.

Exclusion criteria

Exclusion criteria: ?Subjects undergoing depression treatment. ?Subjects who have taken Kampo medicines within the last 4 weeks. ?Subjects who have taken antibiotics within the last 4 weeks. ?Subjects who clearly need Western medical care. ?Subjects diagnosed with ulcerative colitis or Crohn's disease. ?Subjects with hepatic dysfunction or renal dysfunction. ?Subjects who participated in other clinical studies within 12 weeks before the start of study. ?Subjects judged by the attending physician to be ineligible.

Design outcomes

Primary

Measure	Time frame
Changes in the amount of alpha-defensin secretion due to Hangekobokuto administration.	—

Countries

Japan

Contacts

Public ContactMariko Sekine

Oriental Medicine Research Center, Kitasato University Center for Evidence-Based-Medicine

omrc-ebm@insti.kitasato-u.ac.jp03-5791-6346

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026